Consun Pharmaceutical Group Limited
CPHGF
$1.08
$0.0747.34%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 412.65M | 396.41M | 379.27M | 371.58M | 365.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 412.65M | 396.41M | 379.27M | 371.58M | 365.06M |
| Cost of Revenue | 100.84M | 99.42M | 97.79M | 95.83M | 94.18M |
| Gross Profit | 311.81M | 296.98M | 281.49M | 275.75M | 270.88M |
| SG&A Expenses | 178.67M | 173.40M | 167.74M | 164.97M | 162.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.44M | -5.49M | -8.51M | -8.38M | -8.25M |
| Total Operating Expenses | 277.06M | 267.34M | 257.01M | 252.42M | 248.63M |
| Operating Income | 135.59M | 129.07M | 122.26M | 119.16M | 116.43M |
| Income Before Tax | 141.87M | 134.79M | 127.40M | 124.39M | 121.76M |
| Income Tax Expenses | 14.29M | 12.73M | 11.13M | 10.97M | 10.85M |
| Earnings from Continuing Operations | 127.57 | 122.06 | 116.28 | 113.41 | 110.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -963.00K | -709.60K | -453.90K | -366.80K | -278.90K |
| Net Income | 126.61M | 121.35M | 115.82M | 113.05M | 110.63M |
| EBIT | 135.59M | 129.07M | 122.26M | 119.16M | 116.43M |
| EBITDA | 143.47M | 138.04M | 132.31M | 129.22M | 126.54M |
| EPS Basic | 0.15 | 0.15 | 0.15 | 0.14 | 0.14 |
| Normalized Basic EPS | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 |
| EPS Diluted | 0.15 | 0.15 | 0.14 | 0.14 | 0.14 |
| Normalized Diluted EPS | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 |
| Average Basic Shares Outstanding | 3.28B | 3.24B | 3.19B | 3.18B | 3.16B |
| Average Diluted Shares Outstanding | 3.33B | 3.28B | 3.23B | 3.21B | 3.20B |
| Dividend Per Share | 0.08 | 0.08 | 0.08 | 0.07 | 0.06 |
| Payout Ratio | 74.67% | 71.46% | 68.02% | 55.33% | 41.94% |